Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
untohim,
you stated"....imho thing with field days is those who had their days may in turn may be the target of another's field day altogether one day or they will be a coward in their own field forever which usually is the case "
I believe you are insinuating shorts/basher's are about to become toast?
I agree. The lawyer who argued for ctix(now ipix) was Michael Sullivan. He possesses an opposite makeup to Whitey Bulger(google him if you must), but both were born and raised in close proximity.
Sullivan will go for the kill.
I propose this Van Morrison song become the Innovation Pharmaceuticals Inc theme song.
Eveyone's taste in music is different. Hope all enjoy.
www.youtube.com/watch?v=QXMwEsfUBUo
loanranger,
Please, stop making sense:
p.s- don;t see how it would've other than perhaps needing some additional patients for a 200mg arm
Dud,
I don't think anyone is thrilled with current sp, but look back to what was said in their 9/13/16 press release(business update).
From 9/13/16 pr:"Leo Ehrlich, Chief Executive Officer, commented, "We are extremely pleased with the tremendous progress that we have made, especially within the last 12 months. We have assembled an attractive portfolio of three unique compounds, each of which addresses very large markets and is supported by strong IP protection. To date, we have met all of the primary endpoints in each of our clinical trials, and we have a number of very important milestones upcoming during the course of the next 12 to 18 months. Many of these milestones have the potential to create a substantial inflection (turning) point in our market cap."
I'm sure you're capable of doing the math. 12 months from 9/13/16 is (was) 9/13/17, and 18 months from 9/13/16 is 3/13/18. They are within their forecasted range by my math.
I think all would like info asap, but.....
groton68,
"All this nonsense about not enough cash to do these phase 3. It’s a non starter."
I'm sure it's(cash) a primary focus of ipix management as they don't know for sure how recently completed trial results will unfold(hence the recent SF conference, likely booked long ago). I'm sure cash flow is the primary starting thought each working day(and likely, non working day for Erlich and Menon(if not, something's very wrong)).
You state,"We have assets of value. How many and how much we will know shortly." The word believe is the big word missing between your two first words, we, and, have.
You state, "We have assets of value. How many and how much we will know shortly." Most biotechs believe they have "assets of value". Some are correct in their beliefs of value(even underestimated them, more, I believe, overestimate. Trial results determine the value. All we have currently is prilimnary results(which sound good). Final results shall determine whether we are the cat's meow or the cow's dung.
I trust most of have experienced both cases(I know I have). The forward looking statement act of the 1930's, and still required today of publically traded companies was put in for a reason.
Figured I would lighten things up a bit. I believe ipix functions with good intentions, but they seem to operate with the same charima as F-Troop. Is Leo Captain Wilton Parmenter(Ken Berry) or Corporal Randolph Agarn(Larry Stork)?
georgejjl,
If prurisol can sustain those numbers I would say it's a lock and bp must be in fisticuffs for a deal since it's a pill.
The only comparable I can find is from Leo Pharmaceuticals(no joke) product, Kyntheumm. It's approved in Europe to treat moderate-severe psoriasis and is now in 5000 patient phase 4 study.
Avaiable comparisons:
Prurisol (200 mg group)
• IGA changes noted as soon as Week 2
• Progressive decrease of IGA scores to lower values over 12 weeks
• At Week 12, 42.8% subjects (ITT) and 55.0% subjects (PP) achieved “clear” (0) or “almost clear” (1) in IGA
________________________________________
September 14, 2017 03:01 AM Eastern Daylight Time
BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR DISTRIBUTION IN THE UNITED STATES
LEO Pharma today announced new Phase III data broadening the evidence base for the efficacy, safety and quality of life benefits of Kyntheum® (brodalumab), a biologic treatment for people with moderate-to-severe plaque psoriasis. Results from a long-term extension study found Kyntheum® provided sustained high levels of skin clearance (PASII 100) over more than two years in those with moderate-to-severe disease.1 Separate pooled analyses from the AMAGINE clinical trials showed that patients receiving Kyntheum® reported significant health-related quality of life improvements versus placebo.2,3 These data were presented at the 26th European Academy of Dermatology (EADV) annual congress in Geneva, Switzerland.
Psoriasis is a serious, lifelong condition impacting emotional, psychological and physical health. Although its systemic nature often remains unrecognised, people living with psoriasis are at an increased risk of developing serious associated conditions, which further impact quality of life.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.5 For these reasons, lasting skin clearance of symptoms and plaques is an important treatment goal, especially for those with the most severe forms of the disease.5
Results from the AMAGINE-2 extension study confirmed Kyntheum® was able to deliver completely clear skin (PASI 100) in more than half of patients (56.2%, n=779) and almost clear skin (PASI 90) in more than three-quarters of patients (76.8%, n= 779) after two years (120 weeks) of treatment.1 The proportions of patients achieving high levels of skin clearance were comparable to results at year one (week 52) (with 53% and 78% of patients achieving PASI 100 and PASI 90, in year one respectively).1 At week 120, Kyntheum® continued to be well-tolerated with a comparable safety profile, as observed in the 52-week study.1 The most common adverse events were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection, arthralgia (joint pain), and headache.1
“These new data are encouraging as they demonstrate the potential long-term efficacy and safety of Kyntheum® and reinforce its ability to provide psoriasis patients with high levels of lasting skin clearance. It is important that people with moderate-to-severe plaque psoriasis have treatment options that help them to not only achieve clear, healthy skin, but also the capability to relieve the substantial burden the disease places on patients’ everyday lives,” commented Professor Dr. Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.
The burden of psoriasis on quality of life is comparable to other chronic conditions like diabetes and heart diseases.6 Measuring improvements in health-related quality of life is important as they reflect a patient’s experience or perception of disease impact, which is not evaluated by PASI scores alone.7
New pooled analyses of the Phase III AMAGINE(-1,-2,-3) studies showed that significantly greater improvements in health-related quality of life were experienced with Kyntheum® compared with placebo, as measured by the Dermatology Life Quality Index (DLQI)II questionnaire.2,3 At week 12, 59% of Kyntheum® patients reported psoriasis had no impact on their overall quality of life compared to 6% of patients on placebo.3 This was experienced specifically with significant improvements across daily/leisure activities, as well as work/school lives.2 Furthermore, at week 12, 43% of Kyntheum® patients were no longer embarrassed or self-conscious about their psoriasis.3[color=red][/color]
georgejjl,
Hope you are right, but, must say, I read your posts with caution. At this time last year, and for the few months prior to 1/2017, you proclaimed (very often) that the sp would TRIPLE by feb 2017. Nice call, the sp closed at $1.03 the week of 1/23/17.
I read your posts for educational purposes only. Your posts are proof positive examples for me as I(we) try and guide and teach our children the importance of justifying ones statements with indisputable proofs, and therefore proving the statement.
p.s- you change your user name to Humpty-Dumpty. Your status has taken a great fall
p.s.s- I truly hope all your optomistic posts bear fruit. Sometimes it pays to bite your tounge.
glta
Compare this(https://clinicaltrials.gov/ct2/show/NCT02935582?term=Enstilar&rank=3) to prurisol. If prurisol gets approved I wouldn't be surprised to see it included in this trial. Pretty thorough trial.
I'm hoping for good results for all indications based on the info provided by the company(ipix) officers but find it perplexing that ipix's statements can not penetrate much beyond this message board.
Don't bother responding, I am putting you on ignore(I've never done that b4). You must have put Barnum and Bailey out of business as their last carnival barker.
Is Leo Pharma an acuatal entinity? Is that your question??
Oh Boy!. And I'm long.
DaubersUP.
I can't respond to all your questions, but offer this:
A. Prurisol phase 2b topline data?
Response: https://www.businesswire.com/news/home/20170914005082/en/LEO-Pharma-announces-patients-Kyntheum%C2%AE-brodalumab-maintain
B. Kevetrin Oral formulation Update?
https://globenewswire.com/news-release/2018/01/04/1283320/0/en/Celsion-Announces-FDA-Clearance-of-the-OVATION-II-Study-for-the-Evaluation-of-GEN-1-Immunotherapy-to-Treat-Newly-Diagnosed-Stage-III-IV-Ovarian-Cancer.html
C. where were these trials held, and, with whom?
D,E,F,- All brilacidin. Best bet as far as i'm concerned, if they (ipix) is telling the truth.
What(where) is the source of qoute, Leo?
George,
Thanks for another cut and paste, WHICH EVERYBODY HAS SEEN,MORE THAN THEY WOULD LIKE, THANKS TO YOU.
No idea.
George likely has the answers to your questions.
George,
Please do not insult ones intelligence. Makes me think you are a short, and know Leo is blowing smoke(in my mind, because you know him personally).
Your arguements(proofs) are baseless. Please(I think I speak for most, both true long and shorts), give it up.
I believe Galera already has funding partners.
https://www.fiercebiotech.com/venture-capital/novo-and-nea-back-a-37m-round-for-a-biotech-focused-on-cancer-side-effects
sox040713,
I abosolutley enjoy your posts for the pointedness to which your arguments counter.
However, if I may, presenting past and successful sales of other agreements, at this stage of ipix's progress, provides only the tempestuous to counter back, imo(ipix is otc, need I say more).
Take the (Bill) Belichik route. I trust you know what I mean.(He was likley raised in the "bite your tounge generation").
Good luck to us all!
Go PATS;)
P.S- some tough games this past weekend, as it should be this time of year. Like investing, questions in games(results) are never ending.
George,
You underestimate ipix's drug pipeline potential, imo. Trillions in by my estimation.
Good luck.
P.S- Sox040713, hope you are enjoying the PAT's game(though, like ipix's studies, at this point we do not know the final result(Patriots 21, Tennessee 7 at halftime) are in the future(1-1/2 hrs+_).
I hope my point istaken to heart by others.
Neither you, nor anyone of us, knows that. It depends on results and the ability of management's negotiating skills.
Like all biotech's, study results are not guaranteed, which is why publicly traded companies must declare the forward looking statement clause from the 1930's.
In reply to:
you are talking a multiple of 10 times current share price on any deal.....imo
Goodnight, Irene
PP,
I agree, well said.
Cabel, I am like Infinity about 30 % of time, especially in the mornings.
I don't know about balanced opinions. Mine are skewed with my base optimism, which I need to keep in check. Guys like Infinity do help in that and I do appreciate it.
Here Today,
I, for one, certainly yearn for good outcomes(higher share price for all), but please recall it(the conference) was carried on for 3 days, not two(granted, ipci was there for two, 1/8 & 1/9), but the conference was the 8th, 9th and 10 th of January.
We shall soon see Leo's capabilities.
Thanks for the compliment, glad you enjoy them;). I appreciate your posts.
There is a difference(I think) between Pro rated and prorate. On occasion I'll prorate(to divide, distribute, or assess proportionately) my thoughts as I contemplate things.
Regarding shark tank, the brother of our sons friend was on the show. He was the one displaying the product, not the inventor from Philly. They are classmates at a local college.
PP,
I'm beginning to wonder if, perhaps, Leo should audition for Shark Tqnk. Never watched the show until this past Sunday night when our son advised us that he had just received a text from a friend telling him to tune in because his friend's brother was going to be on the show. Ten minutes later(after the presentation), Mark Cuban offered $200,000 down and a 23% royalty on sales.
Ten minutes- done(I'm sure there was plenty more leg work to get there). Point being, there's money out there. The winner of the above noted show has just turned 20 years old and this his second major venture(he's also a college student).
I made an announced visit, and shared the results with those who inquired, I plan to make an un-announced visit soon, just to monitor activity within the office.
Fortunately, I'm close to the office(1 hour), and have family (who may have interest) much closer.
Ditto that(even with the many Mullys I get).
Fore! dollars sp, hopefully sooner than later.
(p.s- the sand wedge is my most used club. I keep a beach towel in the golf bag during extended stays in the trap(s))
I shot a 72 once(18 holes) while playing with the Mulligan's.
Sorry for lack of a question mark after "the question".
I like your estimate, but based on what justification(I very recently posted a deal for an OM drug that struck deal.(p.s. I'm pro ipix, but like to consider good arguments)
Time will tell, but recently Onxeo granted world wide rights to Monopar Therapeutics for Validive(to treat SOM in head and neck cancer patients). From Onxeo 9/13/17 pr: Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive and fund all remaining development, regulatory and commercialization activities.
We shall see.
Cherry pr! Would be nice to see insider support buying at these "low" prices. Why not, say YOU?
Well said. I agree with all you've stated. However,my cousin who died at 54, never gave up and succumbed to peritoneal cancer after pursuing any and all alternatives(chemoed out).
I referenced compassionate use to Dr. M on my visit this week while describing my cousin's fight with peritoneal ovarian cancer(she lost that battle over 4-5 years(tried many treatments, from Boston to California, relying on holistic medicine in the end as she could not tolerate anymore chemo).
That's how i found ipix(ctix) one lucky day many moons ago(sadly,so far, that discovery has helped neither my cousin nor I.)
I visited "the Shoe" this week and spoke with speed stick(no offence intended Dr.(if you read this platform-hope you don't), humor only).
I have no worries with my investment. Convinced the other shoe is about to drop on shorts(and the like).
https://www.cummings.com/ccpage.html
Per the 9/2/17 ipix form 4 filing by A.B indicates held 1,871,246 shares.
The 12/27/17 form 4 filing indicates that, after the transaction((D)238,040 @ $.70), A.B holds 1,633206 shares.
He sold 12.72% of his shares. He still has plenty, but why if good news is right around the corner(which I do believe that).
Source pleade
Let's hypothesize that MAKO and the FUDSTERS are correct and that ipix is a scam.
What does that say about Michael Sullivan and the Ashcroft Law firm?
Judge Failla?
Take a look at the resumes of Sullivan, Ashcroft, and Failla and compare their history to to the likes of MAKO and the ambulance chasing law firm out of NY(almost rhymes with cozen, and appears to operate in cozening ways). That Sullivan et al. are top notch is indisputable. They don't waste time.
If MAKO and fudster's are correct, I'll call Sullivan, but I don't think that's a dime I'll have to drop.
The way I interpret the 5/26/16 pr is that "The primary endpoint was was a 2-point reduction in the IGA score at Day 84."
Couple the above quote from the pr with a sentence a few lines below it in the pr, which notes "As previously released, the trial achieved its primary endpoint in patients treated with 200mg of oral Prurisol."
Anyhow, I believe it is clear that in the 2a trial those who were on prurisol benefited more(at a higher rate) than the placebo arm, with the 200mg dose faring better than the 50mg and 100 mg prurisol arms and the 50 & 100mg prurisol arms fared better than the placebo arm.